Equity Markets Research Report on Keryx ($KERX) as volume increases

Biotech Stock Price and Volume

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing perifosine, a novel, potentially first-in-class, oral anti-cancer agent that inhibits key signal transduction pathways, which are associated with programmed cell death, cell growth, cell differentiation and cell survival. Perifosine is currently in Phase III clinical development for both refractory advanced colorectal cancer and multiple myeloma.

www.EquityMarketsInc.com announced its research report highlighting Keryx Biopharmaceuticals (NASDAQ: KERX) and AEterna Zentaris Inc. (USA) (NASDAQ: AEZS). The research is available with sign-up at:

www.EquityMarketsInc.com/research.php?id=KERX+AEZS.
View the full KERX chart at Wikinvest

KERX has been under pressure since their announcement Monday on:

Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex (Ferric Citrate) Phase 3 Long-Term Study - Study being conducted pursuant to Special Protocol Assessment with the Food and Drug Administration

VFC Stock House @ Seeking Alpha has an updated view on the recent events at KERX and he states:

"While this week's Zerenex update is a noteworthy milestone, by the time the long term Phase III is wrapped up, investors will most likely have a better idea of where the company stands in terms of a partnership or acquisition. In the meantime, KERX could move higher over the next few months leading into trial results and on takeover speculation."

proactive capital

ProActive Capital Indexes

See ProActive's Disclaimer